Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

Adam Hermawan1* and Herwandhani Putri2

Abstract

Background: Several studies have demonstrated the antitumor activity of rosiglitazone (RGZ) in cancer cells, including breast cancer cells. However, the molecular targets of RGZ in the inhibition of angiogenesis in breast cancer cells remain unclear. This study aimed to explore the potential targets of RGZ in inhibiting breast cancer angiogenesis using bioinformatics-based analysis.

Results: Venn diagram analysis revealed 29 TR proteins. KEGG pathway enrichment analysis demonstrated that TR regulated the adipocytokine, AMPK, and PPAR signaling pathways. Oncoprint analysis showed genetic alterations in FABP4 (14%), ADIPOQ (2.9%), PPARG (2.8%), PPARGC1A (1.5%), CD36 (1.7%), and CREBBP (11%) in patients with breast cancer in a TCGA study. The mRNA levels of FABP4, ADIPOQ, PPARG, CD36, and PPARGC1A were significantly lower in patients with breast cancer than in those without breast cancer. Analysis of gene expression using bc-GenExMiner showed that the mRNA levels of FABP, ADIPOQ, PPARG, CD36, PPARGC1A, and CREBBP were significantly lower in basal-like and triple-negative breast cancer (TNBC) cells than in non-basal-like and non-TNBC cells. In general, the protein levels of these genes were low, except for that of CREBBP. Patients with breast cancer who had low mRNA levels of FABP4, ADIPOQ, PPARG, and PPARGC1A had lower overall survival rates than those with high mRNA levels, which was supported by the overall survival related to DNA methylation. Correlation analysis of immune cell infiltration with TR showed a correlation between TR and immune cell infiltration, highlighting the potential of RGZ for immunotherapy.

Conclusion: This study explored the potential targets of RGZ as antiangiogenic agents in breast cancer therapy and highlighted FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP as potential targets of RGZ. These findings require further validation to explore the potential of RGZ as an antiangiogenic agent.

Highlights

- Recent studies have focused on the development of indirect angiogenesis inhibitors.
- Bioinformatics-based identification of potential rosiglitazone target genes to inhibit breast cancer angiogenesis.
- FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP are potential targets of rosiglitazone.

*Correspondence: adam_apt@ugm.ac.id

1 Laboratory of Macromolecular Engineering, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, Yogyakarta 55281, Indonesia

Full list of author information is available at the end of the article
Keywords: Rosiglitazone, Breast cancer, Angiogenesis, Bioinformatics, Targeted therapy

Background
Angiogenesis or neovascularization is the growth of new blood vessels in body tissues that are required by cancer cells to meet their nutrient intake, oxygen, and waste disposal needs for the tumor mass to continue growing and spreading [1]. Angiogenesis allows cells to receive nutrients and oxygen for survival [2]. Cancer initiation, invasion, and metastasis are angiogenesis-dependent events [3]. Most angiogenic also act as anti-metastatic [4].

Angiogenesis inhibitors are divided into two classes: direct and indirect inhibitors [5]. Direct angiogenesis inhibitors, such as canstatin, angiostatin, and tumstatin, directly target endothelial cells and prevent microvascular endothelial cells from responding to various angiogenic proteins, thus inhibiting proliferation, migration of endothelial cell and avoiding cell death [6]. Indirect angiogenesis inhibitors, including tyrosine kinase inhibitors typically block the expression of tumor proteins that trigger angiogenesis or stop their activity, as well as suppress the expression of their receptors in endothelial cells [7].

A peroxisome proliferator-activated receptor-gamma (PPAR) agonist called rosiglitazone (RGZ) is clinically used to treat type 2 diabetes mellitus (T2DM) [8]. Several previous studies have demonstrated the antitumor activity of RGZ in cancer cells, including breast cancer cells [8]. RGZ also increased the sensitivity of MDA-MB 231 cells to tumor necrosis factor-alpha, CH11, and CYC202 [8]. Clinical trials of RGZ early stage breast cancer patients have shown that PPARγ signaling is activated in breast cancer cells [9].

Previous studies have demonstrated that RGZ prevents the growth and angiogenesis of endothelial cells; therefore, it has the potential to be employed as an atherosclerosis treatment [10]. Other studies have shown that the antiangiogenic activity of RGZ in human umbilical vein endothelial cells is mediated by the opening of maxi-K channels due to the activation of PPARγ by RGZ [11]. Another study showed that RGZ inhibits angiogenesis in chick chorioallantoic membranes and endothelial cell migration [12]. A randomized controlled trial of RGZ in humans showed that RGZ reduced adipocyte size and increased capillary density and serum adiponectin levels [13]. RGZ inhibits angiogenesis in myeloma cells by regulating PI3K/Akt and ERK signaling pathways [14]. However, the molecular targets of RGZ in the inhibition of angiogenesis in breast cancer (BC) cells remain unclear.

This study aimed to investigate the potential RGZ target genes in inhibiting breast cancer angiogenesis using bioinformatics-based analysis (Fig. 1). RGZ protein targets were retrieved from the STITCH and STRING publicly available databases, and RGZ potential target genes in angiogenesis inhibition (TR) were identified by analyzing Venn diagrams with breast cancer angiogenesis regulatory genes. Functional annotation of TR, protein–protein interaction (PPI) network, hub gene selection, genetic alteration, and DNA methylation analyses, and KM plots were performed to uncover the potential targets of RGZ in inhibiting angiogenesis. The results of this study could serve as a basis for the development of targeted breast cancer therapy using RGZ to inhibit angiogenesis.

Methods
Data preparation
Direct target proteins (DTPs) from RGZ were obtained from STITCH (http://stitch.embl.de/) [15] based on the default settings from the website. Indirect target proteins (ITPs) from each DTP were retrieved from STRING (https://string-db.org/) version 11.0 [16], with a confidence score setting of 0.4, and the maximum amount of interactions to show was no more than 10. Breast cancer angiogenesis regulatory genes were obtained from OMIM (https://www.omim.org/) [17] with the keywords “breast cancer angiogenesis” and “homo sapiens,” and gene symbols were selected.

Analysis of PPI network and selection of hub genes
PPI network visualization was performed using GENEMANIA (https://genemania.org/) [18] under default settings from the database. Hub genes were selected using Cytoscape version 3.7.1 and CytoHubba plugin [19] based on degree methods in accordance with the default settings from the database.

Functional annotation of the TR
Functional annotation of the TR was performed using ShinyGO v0. 75 (http://bioinformatics.sdstate.edu/go/) using default database settings [20]. Gene ontology assessments of including biological processes, cellular components, and molecular functions, and pathway enrichment network analysis were performed with Fisher’s exact test, using a \( p \) value < 0.05, as a threshold for significance.

Analysis of genetic alterations in selected TR
Genetic alterations analysis in selected TR were conducted using cBioportal (https://www.cbioportal.org/) [21, 22]. In brief, the selected TR (as a gene symbol) was submitted as a query to the database and genetic alterations were searched for among breast cancer studies.
The breast cancer study with the highest amount of genetic alterations was selected for Oncoprint analysis to determine the type of alterations among breast cancer samples. A one-way ANOVA with Tukey's multiple comparison test was used to statistically examine the number of genetic changes in each gene. Mutual exclusivity analysis was performed to explore the mutual alterations among TR gene pairs of TR by Fisher's exact test. Statistical significance was set at \( p \)-value < 0.05.

**DNA methylation analysis of selected TR**

To ascertain the expression and prognostic patterns of single CpG methylation of \( FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, \) and \( CREBBP \) in breast cancer, we used MethSurv (https://biit.cs.ut.ee/methsurv/) [23]. DNA methylation values were depicted in this analysis using beta values (beta values ranging from 0 to 1). The \( \frac{M}{M+U+100} \) equation was used to calculate each CpG methylation. The intensity values M and U were methylated and unmethylated, respectively, as previously described [24].

**Analysis of gene expression in selected TR**

Gene expression was analyzed using GEPIA to determine the expression of selected TR in breast cancer cells and adjacent tissues (http://geopia.cancer-pku.cn/) [25] under default settings from the database. The method for differential analysis was one-way ANOVA. Statistical significance was set at \( p \)-value < 0.01. Targeted expression analysis of selected TR was performed using Breast Cancer Gene Expression Miner v4.5 (bc-GenExMiner v4.5) (http://bcgenex.centregauducheau.fr). In brief, the selected TR was submitted as a gene symbol and searched in the RNA-seq data of TCGA samples from a population of basal-like and triple-negative breast cancer (TNBC) [26]. The differences in gene expression among the different population groups were analyzed using Welch's test. Statistical significance was set at \( p \)-value < 0.01.

**Protein expression in selected TR**

The Human Protein Atlas (HPA, https://www.proteinatlas.org/) was used to determine the protein levels of \( FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, \) and \( CREBBP \) in healthy and malignant breast tissues [27, 28].
**Kaplan–Meier survival analysis**
The prognostic value of TR expression in breast cancer was analyzed using the Kaplan–Meier survival curve from KMPlotter (https://kmplot.com/) based on overall survival (OS) [29]. Statistical significance was set at \( p \)-value < 0.05. The prognostic value of a single CpG of TR in patients with breast cancer was analyzed using the MethSurv database, and the threshold of significance was a likelihood ratio (LR) test, with \( p \)-value < 0.05 [23, 24].

**Correlation analysis of immune cell infiltration with TR**
The correlation of TR with immune cell infiltration was calculated using the TIMER 2.0 database (http://timer.compbio-genomics.org/) [30]. Spearman’s correlation coefficient was used to perform the correlation analysis. An inverse correlation is shown by a negative score, whereas a positive value shows a direct association. A value < 0.05 was considered significant.

**Results**

**Data preparation**
DTPs of RGZ were retrieved from STITCH, yielding 10 proteins: PPARG, PPARA, CD36, RXRA, ADIPOQ, PCK2, UCP2, RETN, SLC2A4, and LEP (Fig. 2A). From each DTP, ITPs were searched for using STRING and 67 ITPs were identified (Supplementary Table 1). All proteins targeted by RGZ, consisting of 10 DTPs and 67 ITPs, were considered RGZ targets. The angiogenesis regulatory gene was obtained from OMIM and produces 1235 regulators, which is referred to as BC angiogenesis (Supplementary Table 2). Analysis of the Venn diagram yielded 29 protein targets that could be potential RGZ targets in inhibiting breast cancer angiogenesis (TR) (Fig. 2B, Supplementary Table 3).

**Analysis of PPI network and selection of hub proteins**
PPI network analysis using STRING version 11.0 produced a network consisting of 29 nodes, 141 edges, an average node degree of 9.72, an average local clustering coefficient of 0.69, an expected edge number of 18, and a PPI enrichment \( p \)-value < 1.0e-16 (Fig. 3A). Hub gene selection based on degree score methods produced the top 10 proteins with the highest scores: INS, ADIPOQ, LEP, PPARG, STAT3, PPARGC1A, CREBBP, EP300, NCOA1, and CD36 (Fig. 3B, Table 1).

**Functional annotation of the TR**
Functional annotation analysis included gene ontology, consisting of biological processes, cellular components, and molecular functions. The TR is in several locations, including the lipopolysaccharide receptor complex, endosome lumen, and chromosome (Fig. 4A). TR plays a role in several molecular functions, including peroxisome proliferator-activated receptor and transcription factor binding (Fig. 4B). TR regulates critical biological processes, such as cellular responses to cytokine stimuli and lipids (Fig. 4C). Analysis of the pathway enrichment network analysis demonstrated that TR regulates adipocytokine, AMPK, and PPAR signaling pathways and miRNAs in cancer (Fig. 4D).

**Analysis of genetic alterations in selected TR**
Genetic alterations in the selected TR were analyzed using cBioportal. FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP were selected as query gene symbols and analyzed using cBioportal. ADIPOQ, PPARG, FABP4, and PPARGC1 were selected based on the degree method using CytoHubba. ADIPOQ, PPARG, and CD36 were the DTPs from RGZ. ADIPOQ, PPARGC1A, and CD36 were DTPs involved in AMPK signaling. PPARG, ADIPOQ, CD36, and FABP4 are involved in PPAR signaling. The TCGA study by Ciriello et al. [31] showed alterations in approximately 24% of the population (Fig. 5A) and was therefore chosen for further assessment. Oncoprint analysis revealed genetic alterations in FABP4 (14%), ADIPOQ (2.9%), PPARG (2.8%), PPARGC1A (1.5%), CD36 (1.7%), and CREBBP (11%) in patients with breast cancer in the TCGA study (Fig. 5B). Further mutual exclusivity analysis revealed that only one gene pair, ADIPOQ-CD36, co-occurred (Table 2).

The copy number alteration analysis showed that the mRNA level of FABP4 was significantly lower in the shallow deletion and higher in the gain and amplification (Fig. 5C). The mRNA level of ADIPOQ was significantly higher in the gain condition. In addition, the mRNA level of CREBBP was significantly lower in the shallow deletion, and significantly higher in the gain and amplification.

**DNA methylation analysis of selected TR**
We demonstrated a heatmap and prognostic value of DNA methylation clustering of the expression levels of FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP in breast cancer (Supplementary Fig. 1). The highest levels of DNA methylation in patients with breast cancer were as follows: cg10062803 and cg14152613 of FABP4; cg06842886, cg14584085, and cg21978128 of ADIPOQ; cg07895576 and cg16827534 of PPARG; cg09427718, cg06772578, and cg08550435 of PPARGC1A; cg05345249 of CD36; cg16560077, cg16562633, cg27390443, cg27318635, cg03140190, and cg05898629 of CREBBP.

**Analysis of the gene expression in selected TR**
TR mRNA levels in breast cancer cells and adjacent tissues were checked using the GEPIA database. The
mRNA expression levels of *FABP4, ADIPOQ, PPARG, CD36, and PPARGC1A* were significantly lower in patients with breast cancer (Fig. 6A), whereas the mRNA levels of *CREBBP* were not different between patients with breast cancer and normal breast tissues. Analysis of gene expression with bc-GenExMiner using TCGA data showed that the mRNA expression levels of *FABP, ADIPOQ, PPARG, CD36, PPARGC1A*, and *CREBBP* were significantly lower in basal-like and TNBC cells than in non-basal-like and TNBC cells (Fig. 6B).

**Protein expression in selected TR**

Protein expression of *FABP4* was not detected in normal breast tissue but was low in breast tumor tissues (Fig. 6C). Protein expression of *ADIPOQ* was not detected in normal breast or breast tumor tissues. Protein expression of *PPARG* was detected at low levels in...
both normal breast and breast tumor tissues. Protein expression of CD36 was detected at a low level in normal breast tissue and at a medium level in breast tumor tissue. PPARC1A data was not available in the HPA database. Protein expression of CREBBP was detected at a medium level in both normal breast and breast tumor tissues. In general, the protein levels of TR were low, except for CREBBP, indicating the potential of RGZ treatment to inhibit angiogenesis by increasing the protein expression.

**Kaplan–Meier survival analysis**

The prognostic value of TR expression in breast cancer was analyzed using Kaplan–Meier survival rate based on OS. Patients with breast cancer who had low mRNA expression levels of *FABP4* (log-rank $P = 0.012$), *ADIPOQ* (log-rank $P = 0.01$), and *PPARG* (log-rank $P = 0.00013$) had worse OS than those with high mRNA levels (Fig. 7).
Moreover, patients with breast cancer showed no significant difference in OS between low- and high-expressing cells of \( \text{CD36} \) (log-rank \( P = 0.75 \)), \( \text{PPARGC1A} \) (log-rank \( P = 0.65 \)), and \( \text{CREBBP} \) (log-rank \( P = 0.37 \)). Additionally, expression levels of DNA methylation analyses revealed that cg14152613 and cg19422565 of \( \text{FABP4} \); cg06842886 and cg16126291 of \( \text{ADIPOQ} \); cg04632671, cg27095527, cg18537222, cg25929976, and cg16827534 of \( \text{PPARG} \); cg11270806 and cg27461259 of \( \text{PPARGC1A} \); cg26136837 and cg18508525 of \( \text{CD36} \) and cg04818078 and cg05194552 of \( \text{CREBBP} \) had the highest levels of DNA methylation and strong predictive value in patients with breast cancer (Supplementary Table 4).

### Table 1 Top 10 network string interactions ranked using the Degree method

| No | Protein Symbol | Degree Score |
|----|----------------|--------------|
| 1  | INS            | 21           |
| 2  | ADIPOQ         | 19           |
| 3  | LEP            | 18           |
| 4  | PPARG          | 14           |
| 5  | STAT3          | 14           |
| 6  | PPARGC1A       | 13           |
| 7  | CREBBP         | 13           |
| 8  | EP300          | 13           |
| 9  | NCOA1          | 11           |
| 10 | CD36           | 11           |

Correlation analysis of immune cell infiltration with TR

Purity was negatively correlated with the expression of \( \text{FABP4} \) (Rho = -0.24, \( p = 1.35e-03 \)), \( \text{ADIPOQ} \) (Rho = -0.296, \( p = 6.98e-05 \)), \( \text{PPARG} \), (Rho = -0.211, \( p = 5.05e-03 \)), and \( \text{CD36} \) (Rho = -0.249, \( p = 9.10e-04 \)) (Table 3, Supplementary Fig. 2). B-cell infiltration was negatively correlated with the expression level of \( \text{CD36} \).
CD8+ cells were positively correlated with PPARGC1A (Rho = 0.234, $p = 1.9\times10^{-3}$) and CREBBP (Rho = 0.2, $p = 8.10\times10^{-3}$). CD4+ cell infiltration was positively correlated with FABP4 (Rho = 0.251, $p = 8.30\times10^{-4}$) and ADIPOQ (Rho = 0.264, $p = 4.28\times10^{-4}$). Dendritic cell infiltration was positively correlated with CREBBP (Rho = 0.229, $p = 2.39\times10^{-3}$). Cancer-associated fibroblast infiltration was positively correlated with the expression levels of FABP4 (Rho = 0.283, $p = 1.52\times10^{-4}$), ADIPOQ (Rho = 0.213, $p = 4.74\times10^{-3}$), PPARG (Rho = 0.199, $p = 8.56\times10^{-3}$), CD36 (Rho = 0.326, $p = 1.12\times10^{-5}$), PPARGC1A (Rho = 0.198, $p = 8.73\times10^{-3}$), and CREBBP (Rho = 0.186, $p = 1.4\times10^{-2}$). Macrophage cell infiltration was positively correlated with the expression levels of FABP4 (Rho = 0.174, $p = 2.14\times10^{-2}$) and CD36 (Rho = 0.246, $p = 1.08\times10^{-3}$), whereas neutrophil cell infiltration was positively correlated with CREBBP (Rho = 0.19, $p = 1.19\times10^{-2}$).

Discussion
This study analyzed the potential of RGZ as an anticanccer drug using bioinformatics approaches. We identified 29 protein targets that could be potential RGZ targets for inhibiting breast cancer angiogenesis (TR). Oncoprint analysis revealed genetic alterations in FABP4 (14%), ADIPOQ (2.9%), PPARG (2.8%), PPARGC1A (1.5%), CD36 (1.7%), and CREBBP (11%) in patients with breast cancer in a TCGA study. DNA methylation is an epigenetic alteration that is involved in breast cancer progression [32]. Methylation of the CpG island gene is known to predict breast cancer progression [33]. DNA methylation analysis revealed that the predictive significance of FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP in a specific CpG was significant in the emergence of breast cancer. This phenomenon indicates the importance of TR as a therapeutic target for breast cancer angiogenesis.

ADIPOQ encodes adiponectin, which is expressed only in adipose tissues [34]. Mutations in this gene result in adiponectin deficiency. Adiponectin levels are
Table 2  Mutual exclusivity analysis of target genes

| A         | B         | Log2 Odds Ratio | p-Value | Tendency     |
|-----------|-----------|-----------------|---------|--------------|
| ADIPOQ    | CD36      | > 3             | 0.017   | Co-occurrence|

regulated by PPARγ signaling through transcriptional and post-transcriptional mechanisms [35]. Adiponectin is secreted by adipose tissue and exhibits anti-cancer, anti-inflammatory, and antioxidant activities [36]. A recent study showed that obesity is a risk factor that is strongly associated with postmenopausal breast cancer [37]. A meta-analysis showed that the genetic variation in ADIPOQ named T45G, is not related to insulin resistance or blood glucose [38]. Polymorphisms in ADIPOQ affect serum adiponectin levels and are associated with breast cancer risk. For example, a previous study found a decrease in serum adiponectin levels and an increase in the risk of breast cancer in patients in Mexico [39]. Genetic variation in ADIPOQ, rs1501299 (G267T), decreases serum adiponectin levels in patients with breast cancer, and an association between ADIPOQ genetic variation and breast cancer risk has been found in patients with postmenopausal breast cancer in Egypt [40]. A recent study found that ADIPOQ is negatively regulated by miR-9-5p, which plays a role in the sensitivity of breast cancer cells to tamoxifen [41]. The effect of RGZ on ADIPOQ on angiogenesis in breast cancer is an interesting topic worth exploring.

PPARG encodes PPARγ. Peroxisome proliferator-activated receptor forms heterodimers with other receptors such as retinoic acid receptors [42]. PPARγ plays an important role in metabolic reprogramming and oxidative phosphorylation, such as electron transport and activation of reactive oxygen species (ROS)-metabolizing enzymes [43]. PPAR signaling has implications in the pathophysiology of skeletal muscle dysfunction in patients with breast cancer [44]. RGZ activates PPARG signaling in endothelial cells [45]. RGZ inhibits metastasis and migration, decreases MMP-2 expression, and prevents angiogenesis by blocking the vascular endothelial growth factor (VEGF) pathway in SGC-7901 gastric cancer cells [46]. In addition, RGZ reduces the risk of breast cancer in patients with T2DM in Taiwan [47]. PPARG1A encodes peroxisome proliferator-activated receptor G coactivator-1a (PGC-1a), a transcriptional coactivator of nuclear receptors and a subfamily member of PPARg [48]. A previous study showed that PGC-1a is a key regulator of angiogenesis and lipid and carbohydrate metabolism [49, 50]. Therefore, further investigation of RGZ-PPARγ signaling in breast cancer angiogenesis is warranted.

CD36 is a cellular scavenger that mediates lipid uptake, recognition of immune responses, inflammation, and apoptosis [51]. CD36 is an 88 KDa transmembrane glycoprotein receptor expressed in various cells, such as monocytes, macrophages, endothelial cells, and adipose cells [52]. CD36 prevents angiogenesis by binding to thrombospondin-1, promoting apoptosis, and inhibiting the VEGFR2 pathway in the endothelial microvessels [53]. In gastric cancer cells, phosphatidylinositol transfer upregulates PPARG and CD36 [53]. RGZ increased the expression of CD36 in rat muscle cells [54]. The effect of RGZ on CD36 in breast cancer angiogenesis is a strategic approach for drug development.

FABP4 or the gene encoding for fatty acid-binding protein 4 (FABP4) is also known as adipocyte FAB or aPA2 and is expressed by adipocytes and macrophages [55]. FABP4 is a chaperone protein found in the cytoplasm, is expressed in adipocytes and myeloid cells, and plays a role in the ubiquitination and degradation of PPARG proteosomes [56]. Several studies have shown that FABP4 plays a role in carcinogenesis. FABP4 is found in stromal cells and can trigger cancer growth by supplying energy to cancer cells or increasing angiogenesis in ovarian cancer cells [57]. Harjes investigated the role of FABP4 and found that FABP4 knockdown inhibited growth, metastasis, and angiogenesis of ovarian cancer in vitro and in vivo [58]. FABP4 suppresses the proliferation and invasion of hepatocellular carcinoma cells and is a predictor of poor prognosis [59]. One study revealed that FABP4 is a pivotal regulator of metastasis in ovarian cancer cells through miR-409-3p modulation [60]. In addition, PPARG signaling activation causes lipolysis mediated by FABP4 and inhibits lung and renal cancer cell growth [61]. Another study showed that serum FABP4 levels increased in patients with colorectal cancer in China compared with normal test subjects, indicating that FABP4 is a risk factor and a potential biomarker [62]. A recent study showed that FABP4 triggers invasion and metastasis in colon cancer through the regulation of fatty acid transport [63]. This study also revealed that FABP4 overexpression triggers epithelial–mesenchymal transition (EMT), upregulates Snail, MMP-2, and MMP-9, and decreases E-cadherin expression. Taken together, these studies indicate that FABP4 is a potential target of RGZ in angiogenesis, and further comprehensive studies are warranted to explore the molecular mechanism of RGZ-targeting FABP4.

CREBBP encodes cyclic AMP-responsive element-binding protein (CREB)-binding protein or CBP, a protein involved in the pathological regulation of diseases such as schizophrenia, embryonic development, and growth control [64]. CREBBP or CBP stabilizes transcription complexes but also exerts intrinsic histone acetyl
transferase (HAT) activity in chromatin remodeling [65]. Mutations in CREBBP have been found in patients with Rubinstein Taybi syndrome and acute lymphoid leukemia [66]. Previous studies have shown that CREBBP plays a role in cancer progression. Deletion of CREBBP occurs in 18.3% of patients with acute lymphoblastic leukemia and encodes a transcriptional coactivator and HAT from CREBBP [66]. Genetic polymorphisms and transcriptional regulation of the CREBBP gene have been observed in patients with large B-cell lymphoma. However, the difference in mRNA levels was not statistically significant between low and high levels of OS and progression-free survival [67]. CREBBP expression abnormalities have been found in patients with lung [68] and prostate [69] cancer [69]. Wang demonstrated that CREBBP mRNA levels are correlated with the expression of metastasis regulator genes such as catenin, cadherin, and EGFR [68]. Further studies on RGZ activity targeting CREBBP in breast cancer angiogenesis are required.

KEGG pathway enrichment analysis demonstrated that TR regulated adipocytokine, AMPK, PPAR, TLR4, and hypoxia-inducible factor (HIF) signaling pathways. Adipocytokines are polypeptides produced by adipocytes that play a role in signaling and are responsible for the development of breast cancer [70]. Activation of HIF signaling increases the expression of VEGF, glycolysis, angiogenesis, and apoptosis regulatory genes [71]. Activation of PPARγ signaling modulated the formation of ROS and the activation of NF-κB and HIFα signaling in mice with an allergic respiratory tract [72]. Moreover, HIF signaling plays an important role in angiogenesis and breast cancer development; thus, HIFs are important therapeutic targets [73].

RGZ targets adiponectin and HIF signaling pathways. It increases serum leptin levels in patients with T2DM [74]. Yee et al. conducted a short clinical trial in patients with breast cancer and found that RGZ treatment increased serum adiponectin levels without serious side effects [9]. Li et al. showed that RGZ attenuated the decrease in ADIPOQ mRNA expression in adipose tissues [75].
Fig. 7  Overall survival in patients with breast cancer related to the mRNA levels of FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP. The plot was considered significant if logrank was $p < 0.05$. 
Another study showed that activation of PPAR signaling by RGZ attenuates HIF signaling [76].

A previous study showed that Toll-like receptor 4 triggers angiogenesis in pancreatic cancer cells by regulating PI3K/Akt signaling [77]. The same authors also showed that TLR4 triggers angiogenesis by activating PI3K/Akt signaling, thereby inducing VEGF expression in pancreatic cancer cells. In esophageal cancer cells, PPARG signaling activation inhibited proliferation and induced apoptosis by inhibiting TLR4-dependent MAPK signaling [78]. Previous studies have revealed that RGZ inhibits TLR4 signaling. In addition, RGZ inhibits the release of TNFα induced by TLR4 signaling through the phosphorylation of p38, JNK, and MAPK during neuroinflammation [79]. A previous in vivo study revealed that RGZ attenuates HIF signaling [76].

Analysis of the prognostic value related to TR expression showed that patients with breast cancer with low mRNA expression levels of FABP4 (log-rank \(P = 0.012\)), ADIPOQ (log-rank \(P = 0.01\)), PPARG (log-rank \(P = 0.00013\)), and PPARGC1A (log-rank \(P = 0.02\)) had worse OS than those with high mRNA levels. Therefore, upregulation of TR during RGZ treatment increases the OS of patients with breast cancer. The analysis performed using TIMER 2.0 showed that B-cell infiltration was negatively correlated with CD36, which is expressed in B-cell subsets because of the immune response to antigens [88]. CD8 infiltration was negatively correlated with PPARGC1A and CREBBP. PGC-1α-overexpressing CD8+ T cells showed enhanced antitumor immunity in a mouse melanoma model [89].

CAF infiltration was positively correlated with FABP4, ADIPOQ, PPARG, CD36, PPARGC1A, and CREBBP. Macrophage infiltration was positively correlated with FABP4 and CD36 levels, whereas neutrophils were positively correlated with CREBBP. FABP4 expression in macrophages is induced by activation of PPARγ signaling [90]. Phagocytosis, mediated by CD36 in apoptotic cells, plays an important role in fibrosis [91].

| Description                  | FABP4  | ADIPOQ  | PPARG  | CD36  | PPARGC1A | CREBBP  |
|------------------------------|--------|---------|--------|-------|----------|---------|
| Purity Rho                   | p 0.24 | p 0.296 | p 0.211| p 0.25 | 0.06     | 0.013   |
| B cell Rho                   | p 1.35e-03 | 6.98e-05 | 5.05e-03| 9.10e-04 | 4.29e-01 | 8.63e-01|
| CD8+ Rho                     | p 0.032 | 0.059   | 0.108  | 0.162  | 0.038    | 0.009   |
| CD4+ Rho                     | p 6.72e-01 | 4.38e-01 | 1.56e-01| 3.26e-02 | 6.23e-01 | 9.10e-01|
| Dendritic cells Rho          | p 0.251 | 0.264   | 0.227  | 0.128  | 0.038    | 0.138   |
| Cancer-associated fibroblasts| p 8.30e-04 | 4.28e-04 | 7.2e-01 | 9.34e-02 | 6.14e-01 | 6.87e-02|
| Macrophage Rho               | p 0.111 | 0.09    | 0.011  | 0.068  | 0.059    | 0.229   |
| Neutrophils Rho              | p 1.46e-01 | 2.38e-01 | 8.88e-01| 3.72e-01 | 4.39e-01 | 2.39e-03|

**Table 3** Correlation between TR expression and Immune infiltration was analyzed using TIMER. Significant values are in bold.

**Description**: Correlation between TR expression and Immune infiltration was analyzed using TIMER. Significant values are in bold.
addition, CD36 functions in tumor-associated immune cells, causing tumor intolerance and progression; thus, it has become a strategic target for cancer therapy [53]. CD36 is expressed in tumor cells, and CD36 deficiency is characterized by stromal tumor and high cancer risk [92]; the lower the CD36 stromal level, the more aggressive the tumor. Taken together, the correlation analysis of immune infiltration of TR emphasized the potential RGZ target gene against angiogenesis in breast cancer by regulating the immune response.

TR plays different roles in the progression of different subtypes of breast cancer. A study by Kim showed that only a few patients with breast cancer express FABP4, including luminal A (0.8%), luminal B (0.7%), HER2+ (6%), and TNBC (4%) [93]. Moreover, FABP4 levels significantly correlated with ER status in patients with breast cancer. FABP4 increases breast cancer cell proliferation in MCF-7 (luminal breast cancer) and MDA-MB-231 triple-negative breast cancer cells, but activation of fatty acid transporters only occurs in MCF-7 luminal breast cancer cells [94]. A previous study showed no correlation between clinicopathologic parameters, including ER, PR, and HER2 status, and FABP expression [95]. FABP4 also plays a critical role in the metastasis and stromal interaction of MDA-MB 231, triple-negative breast cancer cells (TNBC) [96]. Taken together, FABP4 expression levels were not different in any subtype of breast cancer but played a critical role in the progression of ER+ and TNBC.

A previous study demonstrated that serum [97] and protein levels of ADIPOQ were not significantly associated with breast tumor clinicopathology [98]. Recent studies have shown that ADIPOQ is a promising biomarker for TNBC [99] and that lower levels of ADIPOQ are associated with TNBC progression [100]. HER2 overexpression leads to upregulation of CD36 and FABP4 [101]. CD36 is highly expressed in TNBC and plays a role in the fatty acids uptake [102, 103]. Another study showed that CD36 was highly expressed in ER+, moderately expressed in HER2+, and low in TNBC [104]. CD36 increases proliferation and migration of ER+ breast cancer cells [104].

Interaction of ERα and PPARγ inhibits PI3K downstream signaling, which leads to the inhibition of MCF-7 ER+ cells [105]. Crosstalk between PPARγ and ER suppresses the proliferation and migration of thyroid cancer cells [106]. In contrast, stimulation of PPARγ signaling leads to ER inhibition and induces apoptosis in papillary thyroid cancer cells [107]. Overexpression of HER2 induces upregulation of PPARγ transcription and translation in ER+ MCF-7 cells [108]. Moreover, inhibition of PPARγ signaling by its antagonist inhibits breast cancer stem cells in the HER2+ subtype [109]. In contrast, stimulation of PPARγ signaling by PPAR agonists hampers the migration and metastasis of TNBC cells [110].

The expression of PGC-1α, encoded by PPARGC1A, is controlled by the β-catenin pathway in ER+ breast cancer cells [111]. A previous study showed that PGC-1α levels were higher in the HER2+ and the basal subtypes than in other subtypes, which also showed poor prognosis in both subtypes [112]. CREBBP amplification occurs in ER+ and TNBC but not in HER2+ subtypes [113]. Recently, CREBBP was identified as a novel driver of TNBC progression [114]. Taken together, modulation of PPARγ signaling and CREBBP depends on the breast cancer subtype.

This study highlighted six potential target genes that regulate angiogenesis. We propose a mechanism by which RGZ inhibits angiogenesis by targeting TR (Fig. 8). The binding of adiponectin to its receptor ADIPOR1 stimulates AMPK signaling and subsequently increases VEGF expression [115]. In skeletal muscle cells, the activation of AMPK signaling also increases VEGF mediated by PGC1α [116]. Activation of PGC-1α also increased the expression of hypoxia-inducible genes, including HIF-1α [117]. CBP increased the transactivation of NF-κB and its target genes, including VEGF, in endothelial progenitor cells [118]. PPARγ stimulates the expression of VEGFR2 and promotes angiogenesis in endothelial cells [119]. Fatty acids stimulate the expression of VEGF and FABP, which directly modulate angiogenesis in first-trimester placental trophoblast cells and FABP4 increases VEGF expression and induces angiogenesis [120]. Chu showed that CD36 forms a complex with VEGFR2 and promotes VEGF signaling, tube formation, and angiogenesis in microvascular endothelial cells [121]. Another recent study showed that the interaction between CBP and β-catenin increased HIF1α and angiogenesis; however, using a compound, such as E7386, to inhibit this interaction reversed the angiogenesis mechanism [122]. The results of the present study were obtained using a bioinformatics approach. Data mining using another database such as CMap, which connects drugs and gene expression profiles with a certain disease status and predicts the mechanism of the drugs in dealing with certain diseases, can be performed in the future. Further in vitro, in vivo, and clinical trials are needed to validate and develop RGZ as an antiangiogenic agent against breast cancer cells.

**Conclusion**

In this study, the potential of RGZ as an antiangiogenic drug for breast cancer treatment was investigated. This study explored the potential of RGZ as an antiangiogenic agent in breast cancer therapy. We identified FABP4, ADIPOQ, PPARγ, PPARGC1A, CD36, and CREBBP as potential targets of RGZ. We
also investigated the potential role of TR as an immuno-therapy target for RGZ in preventing breast cancer angiogenesis. Future study using in vitro and in vivo experiments are required to expand the therapeutic potential of RGZ against angiogenesis in breast cancer cells.

Abbreviations
AMPK: Activated protein kinase; CREBBP: Cyclic AMP responsive element binding protein-binding protein; DTPs: Direct target proteins; FABP4: Fatty acid-binding protein 4; HAT: Histone acetyl transferase; HIFs: Hypoxia-inducible factors; ITPs: Indirect target proteins; OS: Overall survival; PPARG: Peroxisome proliferator-activated receptor-gamma; PPARGC1A: Peroxisome proliferator-activated receptor G coactivator-1a; PPI: Protein–protein interaction; RGZ: Rosiglitazone; T2DM: Type 2 diabetes mellitus; TNBC: Triple-negative breast cancer; TR: Potential RGZ targets in inhibiting breast cancer angiogenesis; LR: Likelihood ratio.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12863-022-01086-2.

Additional file 1: Supplementary Table 1. Direct target proteins (DTPs) and indirect target proteins (ITPs) of RGZ were analyzed using STITCH and STRING.

Additional file 2: Supplementary Fig. 1. Heatmap of FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP DNA methylation expression levels in breast cancer cells using MethSurv database.

Acknowledgements
The authors thank Badan Penerbit dan Publikasi (BPP) Universitas Gadjah Mada for their writing assistance.

Authors’ contributions
AH was responsible for the conceptualization, data curation, formal analysis, original draft writing, review, and editing of the paper. HP was responsible for data curation and formal analysis, and project administration. The author(s) read and approved the final manuscript.

Declarations
Funding
Not applicable.

Availability of data and materials
The data generated during and/or analysed during the current study are available on the supplementary files.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1 Laboratory of Macromolecular Engineering, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, Yogyakarta 55281, Indonesia. 2 Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, Yogyakarta 55281, Indonesia.
References

1. Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5(2):34.
2. Wang Z, Dabrosin C, Yin X, Fuster MM, Areolla A, Rathamell IK, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35(Suppl):S224-43.
3. Zuazo-Gaztelu I, Casanovas O. Unraveling the role of angiogenesis in Cancer ecosystems. Front Oncol. 2018;8(248).
4. Comunanza V, Bussolino F. Therapy for Cancer: strategy of combining anti-Angiogenic and target therapies. Front Cell Dev Biol. 2017;5:101.
5. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 2003;63(24):8980–9.
6. El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol. 2013;170(4):712–9.
7. Wang J, Zhang L, Pan X, Dai B, Sun Y, Li C, et al. Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents. Sci Rep. 2017;7(1):4145.
8. Mody M, Dharker N, Bloomston M, Wang PS, Chou FS, Glickman TS, et al. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti- tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer. 2007;14(2):305–15.
9. Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, et al. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res. 2007;13(1):246–52.
10. Sheu WH, Ou HC, Chou FP, Lin TM, Yang CH. Rosiglitazone inhibits receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents. Nucleic Acids Res. 2017;45(W1):W98–w102.
11. Gyorffy B, Lanczky A, Ecklund AC, Denkert C, Budciesz J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–31.
12. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–w514.
13. Cirinello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;162(2):506–19.
14. Kiely M, Tse LA, Kolka H, Wang D, Lee P, Wang F, et al. Age-related DNA methylation in paired normal and tumor breast tissue in Chinese breast cancer patients. Epigenetics. 2021;16(6):677–91.
15. Li Y, Melnikov AA, Levenson V, Guerra E, Simeone P, Alberti S, et al. A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer. 2015;15:417.
16. Wang L, Xue X, Wang X, Niu L, Li L, Zhong T, et al. Molecular and functional characterization of the adiponectin (AdipoQ) gene in goat skeletal muscle satellite cells. Asian-Australas J Anim Sci. 2018;31(8):1088–97.
17. Hwang JS, Lee WJ, Hur J, Lee HG, Kim E, Lee GH, et al. Rosiglitazone-dependent dissociation of HUrt from PPAR-y regulates adiponectin expression at the posttranscriptional level. FASEB J. 2019;33(6):7707–20.
18. Estafanis M, Movahedian A, Baranchi M, Goodarzi MT. Adiponectin: an adipokine with protective features against metabolic syndrome. Iran J Basic Med Sci. 2015;18(5):430–42.
19. Mohanty SS, Mohanty PK. Obesity as potential breast cancer risk factor for postmenopausal women. Genes Dis. 2019;8(2):117–23.
20. Cao D, Ouyang S, Liu Z, Ma F, Wu J. Association of the (c/o)ADiPoQ/c/o T45G polymorphism with insulin resistance and blood glucose: a meta-analysis. Endocr J. 2014;61(5):437–46.
21. Cerda-Flores RM, Camarillo-Cárdenas KP, Gutiérrez-Orozco G, Villarreal-Velasco D, Garza-Guajardo P, Ponce-Camacho MA, et al. ADiPoQ single nucleotide polymorphisms and breast cancer in northeastern Mexican women. BMC Med Genet. 2020;21(1):187.
22. Mahmoud EH, Farzay A, El-Din WM, Shafik NE. Diagnostic value of adiponectin gene polymorphism and serum level in postmenopausal obese patients with breast cancer. J Cancer Res Ther. 2020;16(6):1269–73.
23. Liu J, Zhu S, Tang W, Huang Q, Mei Y, Yang H. Exosomas from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p. Cancer Cell Int. 2021;21(1):55.
24. Chiazza F, Collino M. Chapter 9 - Peroxisome Proliferator-Activated Receptors (PPARs) in Glucose Control. In: Mauricio D, editor. Molecular Nutrition and Diabetes. San Diego: Academic Press; 2016. p. 105–14.
25. Quijano C, Trujillo M, Castro L, Trostchansky A. Interplay between oxidant species and energy metabolism. Redox Biol. 2016;8:28–42.
26. Wilson HE, Stanton DA, Rellick S, Geldenhuys W, Pizzutielli EE. Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARγ. Am J Physiol Cell Physiol. 2021;320(4):C577–90.
45. Akiyama TE, Skelhorne-Gross GE, Lightbody ED, Rubino RE, Shi BJ. BMC Genomic Data (2022) 23:72.

48. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome

49. Franks PW, Ekelund U, Brage S, Luan J, Schafer AJ, O’Rahilly S, et al.

51. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved

52. Park YM. CD36, a scavenger receptor implicated in atherosclerosis. Exp

54. Benton CR, Holloway GP, Campbell SE, Yoshida Y, Tandon NN, Glatz JF, Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein

55. Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M. FABP4 attenuates

58. Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Zhong CQ, Zhang XP, Ma N, Zhang EB, Li JJ, Jiang YB, et al. FABP4 suppresses

62. Zhang Y, Zhao X, Deng L, Li X, Wang G, Li Y, et al. High expression of

65. Kim MY, Hsiao SJ, Kraus WL. A role for coactivators and histone acetylation

69. Tang Z, Yu W, Zhang C, Zhao S, Yu Z, Xiao X, et al. CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway. Mol Oncol. 2016;10(2):317–29.

70. Li J, Han X. Adipocytokines and breast cancer. Curr Prob Cancer. 2018;42(2):208–14.

71. Campbell DJ, Dachs GU, Morrin HR, Davey VC, Robinson BA, Vissers MCM. Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. BMC Cancer. 2019;19(1):307.

72. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, et al. Peroxisome proliferator-activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol. 2006;118(1):120–7.

73. de Heer EC, Balvanera P, Harris AL. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest. 2020;130(10):5074–87.

74. Kim HJ, Kim SK, Shim WS, Lee JH, Hur KY, Kang ES, et al. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;81(1):42–9.

75. Li J, Xue YM, Zhu B, Pan YH, Zhang C, et al. Rosiglitazone elicits an adiponectin-mediated insulin-sensitizing action at the adipose tissue-liver Axis in Otsuka long-Evans Tokushima fatty rats. J Diabetes Res. 2018;2018:4627842.

76. Liu K, Yang Y, Liu D, Qiu Y, Zhang C, Zhao J, et al. Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway. Oncotarget. 2016;7(28):27432–82.

77. Zhao H, Orhan YC, Zha X, Esencan E, Chatterton RT, Bulun SE. AMP-activated protein kinase and energy balance in breast cancer. Am J Transl Res. 2017;9(2):197–213.

78. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase inhibitors can activate the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004;321(1):161–7.

79. Sozio MS, Lu C, Zeng Y, Liangpunsakul S, Crabb DW. Activated AMPK inhibits PARP-epsilon and PARP-gamma transcriptional activity in hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2011;301(4):G739–47.

80. Shastmann N, Woods A, Spengler K, Heslegrave A, Bauer R, Krause S, et al. Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. J Biol Chem. 2010;285(14):10638–52.

81. Cao W, Li J, Hao Q, Vagda NV, Wu Y. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019;21(1):29.

82. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther. 2006;5(2):430–7.

83. Hahn SS, Tang Q, Zheng F, Zhao S, Wu J, Chen J. Repression of integrin-linked kinase by antibiotics drugs through cross-talk of PPAR- and...
Won WJ, Bachmann MF, Kearney JF. CD36 is differentially expressed on B cell subsets during development and in responses to antigen. J Immunol (Baltimore, Md : 1950). 2008;180(1):230–7.

Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, et al. Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol Immunol. 2021;18(7):1761–71.

Gautier EL, Chow A, Spanboek R, Marcelin G, Gretter M, Jakubzick C, et al. Systemic analysis of PPARs in mouse macrophage populations reveals marked diversity in expression with critical roles in resolution of inflammation and airway immunity. J Immunol (Baltimore, Md : 1950). 2012;189(5):2614–24.

Pannathur S, Pasichnyk K, Bahrami NM, Zeng L, Febbraio M, Yamaguchi I, et al. The macrophage phagocytic receptor CD36 promotes fibrogenic pathways on removal of apoptotic cells during chronic kidney injury. Am J Pathol. 2015;185(2):2232–45.

Tanase C, Gheorghisan-Galateanu AA, Popescu IC, Mihai S, Codrici E, Albulescu R, Hinescu ME. CD36 and CD97 in Pancreatic Cancer versus Other Malignancies. Int J Mol Sci. 2020;21(16):5656.

Kim S, Lee Y, Koo JS. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS One. 2015;10(3):e0119473.

Guaita-Esteruelas S, Bosquet A, Saavedra P, Gumà J, Girona J, Lam EW-F, et al. Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins. Mol Cancer. 2017;16(1):208–17.

Cui Y, Song M, Kim SY. Prognostic significance of fatty acid binding protein-4 in the invasive ductal carcinoma of the breast. Pathol Int. 2019;69(2):68–75.

Apaya MK, Hsiao PW, Yang YC, Shyu LF. Deregulating the CYP2C19/epoxy-Eicosatrienoic acid-associated FABP4/FABPS signaling network as a therapeutic approach for metastatic triple-negative breast Cancer. Cancers (Basel). 2020;12(1):199.

Chen DC, Chung YF, Yeh YT, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237(1):109–14.

Llanos AAM, Lin Y, Chen W, Yao S, Norin J, Chekhmareva MA, et al. Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype. Breast Cancer Res. 2020;22(1):18.

Hu JD, Chen G, Wu M, Huang Y, Tang W. Downregulation of CDC14B in 5218 breast cancer patients: a novel prognosticator for triple-negative breast cancer. Math Biosci. 2020;376(1):10152–153.

Llanos AAM, Yao S, Singh A, Aremu JB, Khabanian H, Lin Y, et al. Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features. Breast Cancer Res Treat. 2021;185(3):785–98.

Ravacci GR, Brentani MM, Tortelli TC, Torrinhas RS, Santos JR, Logullo AF, et al. Docosahexaenoic acid modulates a HER2-associated Lipoprotein phenotype, induces apoptosis, and increases Trastuzumab action in HER2-overexpressing breast carcinoma cells. Biomed Res Int. 2015;2015:836562.

DeFilippis RA, Chang H, Dumont N, Rabbain, JT, Chen Y-Y, Fontenay GV, et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor TissuesCD36 mediates phenotypes of breast density and Desmoplasiain. Cancer Discovery. 2012;2(9):826–39.

Casciano JC, Perry C, Cohen-Novak AJ, Miller KD, Vande Voorde J, Zhang Q, et al. MYC regulates fatty acid metabolism through a multi-genic program in claudin-low triple negative breast cancer. Br J Cancer. 2020;122(6):6868–84.

Liang Y, Han H, Liu L, Duan Y, Yang X, Ma C, et al. CD36 plays a critical role in proliferation, migration, and tamoxifen-inhibited growth of ER-positive breast cancer cells. Oncogenesis. 2018;7(12):98.

Bonofoligo D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, et al. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin Cancer Res. 2005;11(7):6139–47.

Chu R, van Hasselt A, Vlantis AC, Ng EK, Liu SY, Fan MD, et al. The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer. Cancer. 2014;120(1):142–53.

Yang S, Gong Z, Liu Z, Wei M, Xue L, Vlantis AC, et al. Differential effects of estrogen receptor alpha and Beta on endogenous ligands of peroxisome proliferator-activated receptor gamma in papillary thyroid Cancer. Front Endocrinol. 2021;12:708248.

Yang Z, Bagher-Yarmand R, Balasenthi S, Hottobagyi G, Sahin AA, Barnes CJ, et al. HER2 regulation of peroxisome proliferator-activated receptor gamma expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res. 2003;9(8):3198–203.

Wang X, Sun Y, Wong J, Conklin DS. PPARY maintains ERBB2-positive breast cancer stem cells. Oncogene. 2013;32(49):5512–21.

Wang Y, Zhu M, Yuan B, Zhang K, Zhong M, Yi W, et al. VSP-17, a new PPARγ agonist, suppresses the metastasis of triple-negative breast cancer via upregulating the expression of E-cadherin. Molecules. 2018;23(1):121.

Vergara D, Stanca E, Guerra F, Prone P, Gaballo A, Franck J, et al. β-Catenin knockdown affects mitochondrial biogenesis and lipid metabolism in breast cancer cells. Front Physiol. 2017;8:544.

McGuirk S, Gravel S-P, Deblois G, Papadopoli DJ, Faubert B, Wegner A, et al. PGC-1α supports glutamine metabolism in breast cancer. Metabolism. 2013;1(1):1–11.

Ramadan WS, Talaat IM, Hachim MY, Lischka A, Gemoil T, El-Awady R. The impact of CBP expression in estrogen receptor-positive breast cancer. Clin Epigenetics. 2021;13(1):72.

Peck B, Bland P, Mavrommatis I, Muirhead G, Cottam H, Wei PT, et al. 3D functional genomics screens identify CREBBP as a targetable driver in aggressive triple-negative breast cancer. Cancer Res. 2021;81(14):8479–549.

Bloemer J, Pinky P, Govindarajulu M, Hong H, Judd R, Amin R, et al. Role of adiponectin in central nervous system disorders. Neurol Plast. 2018;2018:1–15.

Leick L, Hellsten Y, Fentz J, Lyngby SS, Wotzczewski JF, Hidalgo J, et al. PGC-1α mediates exercise-induced skeletal muscle VEGF expression in mice. Am J Phys Endocrinol Metab. 2009;297(1):E92–103.

Shaog J, Anany Z. Regulation of hypoxia-inducible genes by PGC-1α. Arterioscler Thromb Vasc Biol. 2010;30(4):662–6.

Jiang H, Chen SS, Yang J, Chen J, He B, Zhu LH, et al. CREB-binding protein silencing inhibits thormin-induced endothelial progenitor cells angiogenesis. Mol Biol Rep. 2012;39(3):2739–52.

Fujii M, Inoki K, Konoshita T, Kono T, Miyamori I: aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma. J Steroid Biochem Mol Biol. 2012;129(3):2739–52.

Basak S, Das MK, Duttaroy AK. Fatty acid-induced angiogenesis in first trimester placental trophoblast cells: possible roles of cellular fatty acid-binding proteins. Life Sci. 2013;93(21):755–62.

Chu LY, Ramakrishnan DP, Silverstein R. Thrombomodulin-1 mediates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells: Blood. 2013;121(18):1822–32.

Kimura M, Hori Y, Kuronishi M, Kimura T, Ichikawa K, et al. Akt-mediated induction of CD36 expression upon PPARγ agonist treatment in HER2-overexpressing breast cancer cells. J Steroid Biochem Mol Biol. 2012;129(3):2739–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.